Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

209 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is local prospective multicenter observational non-interventional local study. Primary study objective is investigate and describe prescription pattern of neurologists in secondary stroke or non-CNS (non-Central Nervous System) systemic embolism prevention in patients with AF (Atrial fibrillation) and prior stroke or TIA (Transient Ischemic attack) who treat with rivaroxaban at an initial visit and three follow-up visits.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Berlin Atrial Fibrillation Registry

NCT02306824

Acute Ischemic Stroke Atrial Fibrillation

COMPLETED

The Care of Stroke in Ziekenhuis Oost-Limburg

NCT03355690

Stroke

COMPLETED

International PFO Consortium

NCT00859885

Stroke Transient Ischemic Attack

UNKNOWN

Improved Prevention of Stroke in Primary Care in Stockholm, Sweden (Förbättrad Prevention av Stroke)

NCT01942031

Ischemic Stroke Hemorrhagic Stroke TIA +1 more

COMPLETED NA

A Comparison of Cognitive Function After Carotid Endarterectomy and Stenting

NCT02220595

Carotid Artery Occlusive Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Embolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Rivaroxaban ( Xarelto, BAY59-7939)

Intervention Type OTHER

Patients with prior stroke or TIA history and who have never taken anticoagulation treatment regarding AF before. One film-coated tablet contains Rivaroxaban 15 mg or 20mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rivaroxaban ( Xarelto, BAY59-7939)

Patients with prior stroke or TIA history and who have never taken anticoagulation treatment regarding AF before. One film-coated tablet contains Rivaroxaban 15 mg or 20mg

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients ≥ 18 years old who start treatment with rivaroxaban
* Non-valvular Atrial Fibrillation is documented in patients' file
* Prior TIA/Stroke history
* TIA - more than 72 hours after documented TIA
* more than 2 weeks after non-hemorrhagic stroke
* Written informed consent

Exclusion Criteria

* Contraindications for use of Xarelto® in accordance with approved product label
* Previous thromboprophylaxis treatment with anticoagulants prior toby reason of stroke / TIA prevention
* Any reasons of medical and non-medical character, which in the opinion of the physician can hamper patient participation in NIS

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No